Glenmark Pharmaceuticals Ltd has received tentative approval by the United States Food and Drug Administration (USFDA) for Nentenab Capsules, 100 mg and 150 mg, the generic version of Ofev@1 Capsules, 100 mg and 150 mg, of Beohringer Ingelheim Pharmaceuticals, Inc.
According to IQVIA sales data for the 10 month period ending April 2021, the Ofev@1 Capsules, 100 mg and 150 mg market achieved annual sales of approximately $1.6 billion.
Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…